複雑性尿路感染症に対するFosfomycinとDibekacin併用療法の臨床的検討

Abstract

複雑性尿路感染症にFOM 4g/day点滴静注とDKB 200 mg/day筋注同時投与により平均5.3日間おこなった効果をUTI薬効評価基準により判定した.1)総合効果判定は, 著効3例, 有効8例, 無効4例で有効率は73.3%であった.2)膿尿に関して正常化5例, 減少5例, 不変5例で, 細菌尿については陰性化8例, 減少2例, 菌交代1例および不変4例となった.3) UTI疾患病態別臨床効果については, 単独感染例11例の有効率は81.8%, 混合感染例4例では50%の成績を得た.4)細菌学的効果は, 投与前に検出された19株中12株が消失し, 7株が存続した.5)副作用は16例につき検討し, Transaminase値の一過性の軽度上昇を2例でみたが, 重篤な副作用は認めなかった

Clinical studies were performed on combination chemotherapy with Fosfomycin and Dibekacin. Sixteen patients with complicated urinary tract infections were treated with a combination of Fosfomycin (4 g/day, d.i.v.) and Dibekacin (200 mg/day, i.m.) for 5 days; and, 15 of them were clinically evaluated by criteria of UTI committee. The clinical effects proved excellent in 3 patients, good in 8 patients, and poor in 4 patients overall effective rate was 73.3%. Out of 19 strains isolated from the patients, 12 strains disappeared after the therapy. No side effect was observed in 16 cases. Clinical use of the combination chemotherapy with Fosfomycin and Dibekacin was thought to be effective and safe for patients with complicated urinary tract infections, because the combination acts not only synergistically, but also because Fosfomycin acts to protect against the nephrotoxicity induced by Dibekacin.